Comparative Pharmacology
Head-to-head clinical analysis: ADALAT CC versus VERELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT CC versus VERELAN.
ADALAT CC vs VERELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Verapamil inhibits calcium ion influx across cardiac and smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and negative chronotropic, dromotropic, and inotropic effects.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Hypertension: 120-240 mg ER orally once daily; maximum 480 mg/day. Angina: 80-120 mg IR orally three times daily; ER 180-360 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Terminal elimination half-life is 2.8 to 7.4 hours in healthy adults, prolonged in hepatic impairment or elderly (up to 12 hours).
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Renal excretion accounts for approximately 70% of elimination, with 3-4% as unchanged drug. Fecal elimination accounts for about 25%, predominantly via biliary secretion.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker